Compare Crispr Therapeutics AG (CRSP) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Howmet Aerospace Inc — how do they compare? Crispr Therapeutics AG trades at $50.53 (market cap $4.97B), while Howmet Aerospace Inc trades at $273.89 (market cap $110.74B). The key difference: Howmet Aerospace Inc is far larger — about 22.3× Crispr Therapeutics AG's market cap, and Howmet Aerospace Inc pays a 0.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HWM | |
|---|---|---|
Market Cap | $4.97B | $110.74B |
Sector | Health | Industrials |
52-Week High | $76.78 | $283.23 |
52-Week Low | $44.34 | $171.00 |
Enterprise Value | $3.32B | $112.99B |
Dividend Yield | — | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Howmet Aerospace (HWM) trades at $271.28, up 0.16% on the day, with a neutral technical signal but strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.22 exceeding expectations. Revenue growth and robust profit margins, including a 20.22% net income margin, support its premium valuation multiples. Recent news highlights strength in commercial aerospace demand as a key growth driver.
The outlook remains positive given analyst consensus with 84% buy ratings and a $317.63 price target, suggesting ~17% upside. However, elevated valuation ratios like a P/E of 64.22 pose risks if growth slows. Key catalysts include Q2 2026 results on August 6, 2026, while reliance on aerospace cycles and competitive pressures are monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
